Spencer B Gibson Selected Research

Lu 28-179 (Siramesine)

11/2022	Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors.
1/2019	Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels.
1/2018	Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells.
1/2017	Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Spencer B Gibson Research Topics

Disease

39	Neoplasms (Cancer) 02/2024 - 01/2002
30	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 11/2003
11	Breast Neoplasms (Breast Cancer) 02/2024 - 01/2002
11	Hypoxia (Hypoxemia) 11/2021 - 07/2003
4	Glioma (Gliomas) 01/2019 - 04/2009
4	Hematologic Neoplasms (Hematological Malignancy) 01/2012 - 01/2008
3	Necrosis 01/2019 - 06/2008
3	Lymphoma (Lymphomas) 01/2018 - 01/2008
3	Ovarian Neoplasms (Ovarian Cancer) 12/2012 - 03/2004
3	Leukemia 12/2010 - 08/2003
2	Melanoma (Melanoma, Malignant) 02/2024 - 05/2011
2	Lymphocytosis 01/2023 - 01/2019
2	Mitochondrial Diseases (Mitochondrial Disease) 11/2022 - 01/2017
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2022
2	Infections 01/2019 - 03/2014
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018 - 10/2004
2	B-Cell Leukemia (Leukemia, B Cell) 06/2011 - 11/2009
2	Burkitt Lymphoma (Burkitt's Lymphoma) 06/2008 - 07/2006
1	Neoplasm Metastasis (Metastasis) 02/2024
1	Prostatic Neoplasms (Prostate Cancer) 11/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Hypersensitivity (Allergy) 01/2020
1	Skin Neoplasms (Skin Cancer) 12/2019
1	Disease Progression 01/2019
1	Adenocarcinoma of Lung 01/2019
1	Tumor Lysis Syndrome 01/2019
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Plasma Cell Neoplasms 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Genomic Instability 01/2017

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2003
8	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2022 - 04/2009
8	LigandsIBA 01/2016 - 01/2002
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2012
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 07/2003
5	Monoclonal AntibodiesIBA 01/2018 - 02/2006
5	Epidermal Growth Factor (EGF)IBA 01/2014 - 01/2002
5	Death Domain ReceptorsIBA 07/2011 - 11/2003
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2008 - 01/2002
4	Tyrosine Kinase InhibitorsIBA 11/2022 - 09/2007
4	Lu 28-179 (Siramesine)IBA 11/2022 - 01/2017
4	lysophosphatidic acidIBA 12/2009 - 03/2005
3	CytokinesIBA 01/2023 - 09/2007
3	Chlorambucil (Leukeran)FDA Link 02/2022 - 11/2003
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 01/2016
3	IronIBA 01/2019 - 01/2017
3	Lapatinib (GW572016)FDA Link 01/2019 - 09/2007
3	fludarabineIBA 11/2016 - 11/2003
3	NucleosidesIBA 11/2016 - 11/2003
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 07/2011 - 07/2005
3	Transcription Factors (Transcription Factor)IBA 03/2011 - 07/2003
3	Trastuzumab (Herceptin)FDA Link 09/2007 - 07/2003
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 03/2014
2	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 04/2009
2	ibrutinibIBA 03/2020 - 01/2020
2	Bendamustine Hydrochloride FDA Link 10/2019 - 11/2016
2	idelalisibIBA 10/2019 - 01/2018
2	Phosphatidylinositols (Phosphatidylinositol)IBA 10/2019 - 11/2009
2	Alkylating AgentsIBA 11/2016 - 11/2003
2	LipidsIBA 01/2016 - 07/2011
2	Histones (Histone)IBA 11/2014 - 06/2008
2	NAD (NADH)IBA 11/2014 - 01/2009
2	Apoptosis Inducing FactorIBA 11/2014 - 04/2009
2	RNA (Ribonucleic Acid)IBA 03/2014 - 05/2011
2	Histone Deacetylase InhibitorsIBA 01/2014 - 06/2008
2	Small Interfering RNA (siRNA)IBA 01/2013 - 02/2008
2	Oxygen (Dioxygen)IBA 03/2011 - 02/2008
2	Arsenic Trioxide (Trisenox)FDA Link 10/2010 - 04/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2009 - 06/2008
2	Lysophosphatidic Acid ReceptorsIBA 12/2009 - 03/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2008 - 07/2003
2	Etoposide (VP 16)FDA LinkGeneric 02/2008 - 02/2006
1	Interleukin-16 (Interleukin 16)IBA 01/2023
1	ChemokinesIBA 01/2023
1	obinutuzumabIBA 02/2022
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2022
1	Chloroquine (Aralen)FDA LinkGeneric 01/2022
1	epidermal growth factor receptor VIIIIBA 01/2022
1	ElementsIBA 11/2021
1	Misoprostol (Cytotec)FDA LinkGeneric 11/2021
1	Alprostadil (Muse)FDA LinkGeneric 11/2021
1	Histamine Antagonists (Antihistamines)IBA 01/2020
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020
1	Phosphotransferases (Kinase)IBA 10/2019
1	Lenalidomide (CC 5013)FDA Link 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019
1	Immunoglobulin A (IgA)IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Chemokine ReceptorsIBA 01/2018
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	Antimalarials (Antimalarial Agents)IBA 01/2018
1	Cancer VaccinesIBA 01/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018
1	Pregnenolone Carbonitrile (PCN)IBA 01/2018
1	SphingosineIBA 01/2017

Therapy/Procedure

23	Therapeutics 02/2024 - 03/2005
11	Drug Therapy (Chemotherapy) 01/2022 - 07/2003
2	Immunotherapy 02/2024 - 01/2018
1	Time-to-Treatment 01/2019